Protagonist Therapeutics (NASDAQ: PTGX) revenue
Protagonist Therapeutics reported revenue of $46.0m for fiscal 2025, 89.4% less than in fiscal 2024 ($434.4m). Since fiscal 2017 its revenue has grown by 129.4%, an average growth of 10.9% a year.
Protagonist Therapeutics's best year of the last 9 was fiscal 2024. The biggest drop was in fiscal 2019, −99.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $46.0m | −89.4% | −$158.1m | −343.6% |
| 2024 | $434.4m | +624.1% | $252.8m | 58.2% |
| 2023 | $60.0m | +125.7% | −$93.7m | −156.1% |
| 2022 | $26.6m | −2.8% | −$131.4m | −494.2% |
| 2021 | $27.4m | −4.4% | −$125.8m | −460.0% |
| 2020 | $28.6m | +12,293.1% | −$64.5m | −225.4% |
| 2019 | $0.2m | −99.3% | −$80.5m | −34,857.6% |
| 2018 | $30.9m | +54.1% | −$42.3m | −136.7% |
| 2017 | $20.1m | — | −$37.9m | −188.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Protagonist Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Protagonist Therapeutics ranks 329th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Protagonist Therapeutics, −89.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 327th | Ocular Therapeutix | $52.0m | −18.5% |
| 328th | Lexicon Pharmaceuticals | $49.8m | 60.2% |
| 329th | Protagonist Therapeutics | $46.0m | −89.4% |
| 330th | Septerna | $46.0m | 4,174.5% |
| 331st | TriSalus Life Sciences | $45.2m | 53.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Protagonist Therapeutics
- How much revenue did Protagonist Therapeutics make in fiscal 2025?
- Protagonist Therapeutics reported revenue of $46.0m for fiscal 2025, compared with $434.4m in fiscal 2024.
- How much has the revenue of Protagonist Therapeutics grown?
- Between fiscal 2017 and fiscal 2025 it went from $20.1m to $46.0m: 129.4% more, an average growth of 10.9% a year.
- What was the best year for revenue at Protagonist Therapeutics?
- Of its last 9 fiscal years, fiscal 2024, with $434.4m.
- Where does Protagonist Therapeutics rank in its sector by revenue?
- It ranks 329th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Protagonist Therapeutics come from?
- From the annual report (Form 10-K) that Protagonist Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Protagonist Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Protagonist Therapeutics: the Protagonist Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.